Protein Rb's New Role in Breast Cancer Signalling

Researchers have uncovered a previously unknown function of the protein Retinoblastoma (Rb), a key regulator of the cell cycle, which explains a critical aspect of breast cancer progression. Published online on September 7, 2026, in the journal Nature, the study details how inhibiting cell division can paradoxically enhance the signalling mediated by the oestrogen receptor, a primary driver of many breast cancers. This discovery offers new insights into the complex mechanisms underlying oestrogen receptor-positive (ER+) breast cancer, which accounts for approximately 70% of all breast cancer diagnoses. The oestrogen receptor plays a vital role in cell growth and proliferation, and its aberrant activation is a hallmark of ER+ breast cancers.

The protein Rb is well-established as a tumor suppressor, acting as a crucial "gatekeeper" of the cell cycle. It prevents cells from entering the DNA replication phase (S phase) until they are ready. When Rb is functional, it binds to transcription factors, notably E2F, thereby halting cell division. However, in many cancers, including breast cancer, Rb is inactivated through mutations or by viral oncoproteins, leading to uncontrolled cell proliferation. The new research, however, reveals a more nuanced role for Rb beyond its canonical cell cycle control function. It appears that even when Rb's cell cycle inhibitory function is compromised, it can still influence oestrogen receptor signalling pathways.

Specifically, the study found that when cell division is inhibited, perhaps through therapeutic interventions targeting cell cycle progression, the signalling mediated by the oestrogen receptor is amplified. This amplification can, in turn, promote the growth and survival of breast cancer cells. This finding is significant because it suggests that strategies aimed solely at halting cell division might have unintended consequences, potentially making the cancer more aggressive or resistant to certain treatments. The research highlights the intricate interplay between cell cycle regulation and hormonal signalling in the context of breast cancer, a field that has seen extensive study but still holds many unanswered questions.

The implications of this discovery are substantial for the development of novel therapeutic strategies. Understanding how Rb influences oestrogen receptor signalling could lead to the design of combination therapies that simultaneously target cell division and hormonal pathways, or therapies that specifically modulate Rb's interaction with the oestrogen receptor. This could offer more effective treatments for patients with ER+ breast cancer, particularly those who develop resistance to current endocrine therapies. The research was conducted by a team of scientists who utilized advanced molecular biology techniques and cellular models to elucidate these complex interactions. The doi for the publication is 10.1038/d41586-026-02470-z.